TranS1, Inc., based in Wilmington, has received clearance from the U.S. Food and Drug Administration to market its AxiaLIF 2L™ system - a minimally invasive surgical approach to treat degenerative disc disease in the lower lumbar region.
The company's AxiaLIF 2L line enables surgeons to perform multi-level percutaneous lumbar fusion, which means the surgery does not cut through soft tissues like muscles and ligaments, thus lessening patient pain and the likelihood of complications. This minimally invasive approach dramatically reduces the patient's length of hospital stay after surgery and time out of work.
TranS1 is a publicly held medical device company focused on developing innovative, minimally invasive surgical procedures for treatment of low back pain (LBP).